Search Results - "Kato, Masafumi"

Refine Results
  1. 1

    Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan by Kato, Masafumi, Ono, Takayori, Deguchi, Hisato, Ohmagari, Norio, Igarashi, Ataru

    Published in Vaccine: X (01-08-2024)
    “…•NVX-CoV2373 is a vaccine marketed for COVID-19 prevention in Japan.•Its cost-effectiveness was assessed for the first time in elderly people in Japan.•Primary…”
    Get full text
    Journal Article
  2. 2
  3. 3

    DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers by Kato, Masafumi, Takano, Masashi, Miyamoto, Morikazu, Sasaki, Naoki, Goto, Tomoko, Tsuda, Hitoshi, Furuya, Kenichi

    Published in Journal of gynecologic oncology (01-01-2015)
    “…Recent investigations have revealed DNA mismatch repair (MMR) gene mutations are closely related with carcinogenesis of endometrial cancer; however the impact…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review by Miyamoto, Morikazu, Takano, Masashi, Goto, Tomoko, Kato, Masafumi, Sasaki, Naoki, Tsuda, Hitoshi, Furuya, Kenichi

    Published in Journal of gynecologic oncology (01-01-2013)
    “…Compared with serous adenocarcinoma (SAC), clear cell carcinoma (CCC) often shows chemo-resistance, which would potentially lead to a poor prognosis. On the…”
    Get full text
    Journal Article
  7. 7

    Late thrombosis of sirolimus-eluting stent occurring in the perioperative period by Kato, Masafumi

    “…We report a late thrombosis of sirolimus-eluting stent 6 months after implantation of a drug-eluting stent. A 70-year-old man (52 kg, 148 cm) was diagnosed as…”
    Get more information
    Journal Article
  8. 8
  9. 9

    Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden by Deguchi, Hisato, Kato, Masafumi

    Published in Advances in therapy (01-12-2024)
    “…Introduction Short bowel syndrome (SBS) is associated with a significant mental and physical burden for patients and caregivers. Standard of care (SOC) for SBS…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13

    TCTAP C-094 Successful Percutaneous Coronary Intervention for Right Coronary Artery Chronic Total Occlusion Guided by Non-contrast Enhanced CT by Kato, Masafumi, Ueda, Kinzo

    “…Good collateral flow from 1st septal branch to distal RCA was easily identified. [...]we began first PCI tretrogradely. Stent implantation After the…”
    Get full text
    Journal Article
  14. 14

    Multiple criteria qualitative value-based pricing framework “MARIE” for new drugs by Takami, Akina, Kato, Masafumi, Deguchi, Hisato, Igarashi, Ataru

    Published in Health policy and technology (01-12-2024)
    “…•Value-based pricing (VBP) could improve allocation of healthcare resources. We created and evaluated a simple VBP method that qualitatively considers broad…”
    Get full text
    Journal Article
  15. 15

    A case with fistula formation between a perinephric retroperitoneal abscess, a ureter and a descending colon: Successful outcome after conservative management by Iwamoto, Yoichi, Kato, Masafumi

    Published in Canadian Urological Association journal (01-09-2014)
    “…A 72-year-old man diagnosed with hydronephrosis and perinephric abscess because of an impacted urinary stone in the left uretero-pelvic junction was admitted…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19

    Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers by Kudoh, Kazuya, Takano, Masashi, Kouta, Hiroko, Kikuchi, Ryoko, Kita, Tsunekazu, Miyamoto, Morikazu, Watanabe, Akio, Kato, Masafumi, Goto, Tomoko, Kikuchi, Yoshihiro

    Published in Gynecologic oncology (01-08-2011)
    “…Abstract Objectives Currently, pegylated liposomal doxorubicin (PLD) is regarded as one of the standard treatment options in recurrent ovarian cancers (ROC)…”
    Get full text
    Journal Article
  20. 20

    Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement by Takano, Masashi, Kikuchi, Yoshihiro, Kato, Masafumi, Yoshikawa, Tomoyuki, Kita, Tsunekazu

    Published in Gan to kagaku ryoho (01-11-2008)
    “…Recent reports showed that bevacizumab, a humanized recombinant antibody binding to vascular endothelial growth factor (VEGF), harbored a significant activity…”
    Get more information
    Journal Article